US · QDEL
QuidelOrtho Corporation
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- San Diego, CA 92121
- Website
- quidelortho.com
Price · as of 2025-12-28
$12.64
Market cap 1.54B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $21.29 | +68.43% |
| Intrinsic Value(DCF) | $9.04 | -28.48% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $4.64 | $10.76 | |||
| 2012 | $4.56 | $0.95 | |||
| 2013 | $5.15 | $4.27 | |||
| 2014 | $3.83 | $0.00 | |||
| 2015 | $3.19 | $0.00 | |||
| 2016 | $1.46 | $0.00 | |||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $10.80 | $160.91 | |||
| 2019 | $14.38 | $18.61 | |||
| 2020 | $119.81 | $4,031.31 | |||
| 2021 | $121.52 | $171.28 | |||
| 2022 | |||||
| 2023 | $91.57 | $930.49 | |||
| 2024 | $40.80 | $199.18 | $0.15 | $0.00 | $0.00 |
| 2025 | $22.60 | $21.29 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates QuidelOrtho Corporation's (QDEL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $21.29
- Current price
- $12.64
- AI upside
- +68.43%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$9.04
-28.48% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| QDEL | QuidelOrtho Corporation | $12.64 | 1.54B | +68% | -28% | — | — | -1.35 | 0.80 | 0.56 | -8.47 | — | -2.38 | 46.67% | -33.67% | -41.45% | -46.15% | -18.22% | -18.56% | 1.46 | -5.18 | 1.50 | 0.64 | -5.40 | -4535.00% | -189.00% | -2596.00% | -5.42% | 0.11 | -1.65% | 0.00% | 0.00% | 0.00% | -4.50 | -49.82 | 1.51 | 0.29 |
| ATRC | AtriCure, Inc. | $31.26 | 1.56B | +49% | -32% | -90% | — | -129.01 | 3.00 | 2.76 | 86.02 | — | 7.06 | 74.41% | -0.64% | -2.14% | -2.40% | -0.83% | -1.81% | 0.18 | -0.59 | 3.96 | 2.87 | -4.89 | -7474.00% | 1488.00% | -52900.00% | 3.27% | 0.70 | 11.67% | 0.00% | 0.00% | 3.01% | -405.42 | 28.94 | 2.61 | 5.82 |
| AZTA | Azenta, Inc. | $26.98 | 1.24B | +62% | -42% | -40% | — | -28.75 | 0.93 | 2.70 | 25.40 | — | 1.74 | 45.52% | -1.90% | -9.39% | -3.19% | -0.31% | -2.68% | 0.06 | — | 2.98 | 2.23 | -3.12 | -6052.00% | 355.00% | 21029.00% | 2.39% | 0.30 | 2.67% | 0.00% | 0.00% | 0.00% | -121.90 | 35.84 | 2.31 | 4.42 |
| EWTX | Edgewise Therapeutics, In… | $30.44 | 3.22B | — | — | — | — | -18.22 | 5.85 | — | -13.38 | -146.76 | 5.85 | 0.00% | — | — | -34.19% | 3798.11% | -32.29% | 0.01 | — | 19.85 | 19.37 | 0.30 | 1241.00% | — | 3057.00% | -4.71% | -5.25 | 2858.86% | 0.00% | 0.00% | 0.66% | -13.22 | -17.57 | — | 59.04 |
| GPCR | Structure Therapeutics In… | $62.98 | 3.63B | — | — | — | — | -26.37 | 2.46 | — | -16.39 | -1028.46 | 2.46 | 0.00% | — | — | -11.86% | -570.89% | -11.35% | 0.00 | — | 24.81 | 22.85 | 5.69 | 256.00% | — | 9149.00% | -6.06% | -3.51 | -730.15% | 0.00% | 0.00% | 16.85% | -12.94 | -10.11 | — | 33.44 |
| LMAT | LeMaitre Vascular, Inc. | $108.18 | 2.45B | -46% | -51% | -89% | -62% | 41.10 | 5.37 | 8.23 | 25.41 | 93.35 | 7.69 | 68.63% | 23.77% | 20.03% | 13.87% | 18.60% | 9.80% | 0.55 | 254.91 | 13.14 | 10.77 | 2.40 | 4403.00% | 1363.00% | 2603.00% | 2.05% | 1.44 | 17.08% | 0.79% | 32.60% | 0.79% | 32.46 | 45.64 | 7.71 | 6.95 |
| QURE | uniQure N.V. | $15.63 | 962.87M | +52% | -69% | — | — | -2.48 | -88.12 | 21.94 | -1.83 | — | -5.94 | 32.42% | -679.58% | -883.35% | -238.46% | 63.55% | -34.51% | -9.78 | -2.89 | 9.74 | 9.32 | 0.58 | -2396.00% | 7117.00% | 2157.00% | -31.28% | -4.56 | 64.17% | 0.00% | 0.00% | 0.00% | -1.59 | -1.58 | 10.82 | -2.50 |
| TWST | Twist Bioscience Corporat… | $46.92 | 2.88B | -25% | -66% | -100% | — | -24.87 | 4.08 | 5.13 | -35.25 | — | 5.12 | 50.72% | -36.18% | -20.63% | -16.43% | -41.34% | -12.37% | 0.29 | — | 3.64 | 3.17 | 0.88 | -6389.00% | 2032.00% | 934.00% | -3.92% | -0.52 | -22.95% | 0.00% | 0.00% | 0.00% | -13.48 | -24.28 | 4.88 | 4.32 |
| VRDN | Viridian Therapeutics, In… | $29.38 | 2.39B | +11,973% | +7,221% | — | — | -7.49 | 3.55 | 36.21 | -5.16 | — | 3.55 | 98.36% | -512.91% | -483.57% | -49.16% | 573.89% | -41.73% | 0.07 | -73.44 | 12.65 | 12.37 | 0.48 | -1658.00% | 2335993.00% | 1892.00% | -10.79% | -3.91 | 437.27% | 0.00% | 0.00% | 3.24% | -4.79 | -6.29 | 24.58 | 6.44 |
| XRAY | DENTSPLY SIRONA Inc. | $14.68 | 2.93B | +40% | -61% | — | — | -4.77 | 2.13 | 0.78 | -107.57 | — | -3.65 | 50.00% | 6.85% | -16.25% | -36.44% | 6.83% | -10.70% | 1.81 | 2.86 | 1.51 | 0.76 | -45.54 | -3304.00% | -298.00% | -6299.00% | 3.64% | 0.17 | 2.82% | 4.49% | -21.40% | 4.49% | 19.64 | 47.58 | 1.34 | 1.00 |
About QuidelOrtho Corporation
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
- CEO
- Brian J. Blaser
- Employees
- 6.6K
- Beta
- 0.72
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($9.04 ÷ $12.64) − 1 = -28.48% (DCF, example).